Genotypic prediction of tuberculosis drug resistance and implementation of effective MDR-TB management
Leading partner organisation: FZB (Germany)
An effective approach to the management of MDR-TB is to tailor drug therapy regimens on the basis of comprehensive resistance testing. CARE will contribute to this effort by:
-
Helping elucidate MDR-TB epidemiology in Russia and Moldova
-
Developing a genotype-to-phenotype prediction framework based on whole genome sequencing to infer second-line TB drug resistance from genotypic data and ease the choice of personalised treatment
-
Designing and developing a software tool for phenotypic drug resistance prediction by genotype
-
Characterizing host genetic traits that predispose to extrapulmonary TB and are known to be involved in higher susceptibility to HIV
-
Defining and testing a pilot model intervention of personalised effective MDR-TB treatment in Russia and other countries of the former Soviet Union, and designing associated clinical training modules